Accuray Announces First Patient Treatments in New Zealand With the CyberKnife® System, the World's Only Robotic Radiation Therapy Delivery Device

Rhea-AI Summary

Accuray (NASDAQ: ARAY) announced that Auckland Radiation Oncology (ARO) has become the first center in New Zealand to use the advanced CyberKnife S7™ System for precise cancer treatments. This system allows for stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) with high accuracy, often requiring only 1 to 5 outpatient sessions. The CyberKnife System enhances treatment efficiency, enabling ARO to treat more patients daily. CEO Suzanne Winter emphasized that this innovation broadens access to effective cancer care, while ARO’s Clinical Director Dr. Benji Benjamin noted the system’s potential to greatly improve treatment precision and minimize side effects.

Positive

• First implementation of the CyberKnife S7 System in New Zealand enhances treatment options.
• Increases treatment capacity at Auckland Radiation Oncology, allowing more patients to receive care.
• Non-invasive treatment with high precision may lead to improved patient outcomes.

Negative

• None.

Auckland Radiation Oncology Selected the Latest-Generation CyberKnife S7™ System to Deliver Precise Treatments More Quickly, so Patients Can Rapidly Return to the Activities They Enjoy

SUNNYVALE, Calif., Jan. 17, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Auckland Radiation Oncology (ARO) is the first center in New Zealand to treat patients with the CyberKnife^® System, a robotic radiation therapy device known for delivering treatments with sub-millimeter precision and accuracy in typically 1 to 5 outpatient sessions. The ARO medical care team selected the latest generation CyberKnife S7™ System to provide stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) to patients more efficiently, minimizing the time they spend in daily treatments and maximizing the number of New Zealand cancer patients they can treat each day.   

"These first-in-country patient treatments reinforce the value the CyberKnife System provides to medical care teams around the globe. The addition of the Auckland Radiation Oncology center to the network of facilities using the CyberKnife System will broaden access to a trusted radiation therapy treatment option," said Suzanne Winter, president and CEO of Accuray. "We believe the system has the ability to significantly and positively impact the way the Auckland Radiation Oncology team treats cancer and certain neurological conditions, and will enable them to bring new hope to people who previously would have been without options."

The CyberKnife S7 System combines speed, precision and motion synchronization technology for the treatment of lesions and tumors throughout the body. Treatment is non-surgical, non-invasive and does not require incisions or general anesthesia. Clinical studies support the use of the CyberKnife System, expanding medical care team options for achieving outstanding outcomes for a wide range of indications. 

ARO Clinical Director Dr. Benji Benjamin said, "We believe the CyberKnife System is more accurate than traditional radiation therapy, with potentially thousands of smaller beams delivering radiation to the tumor with sub-millimeter precision, minimizing damage to surrounding healthy structures and organs. Introducing the system to our suite of tools is about giving New Zealanders access to one of the world's most advanced treatment options and doing what we can to minimize the impact of an already challenging time in people's lives."

Dr. Ian Hanson, ARO's Chief Physicist, added, "During treatment, the CyberKnife System will detect any movement of the patient or the tumor and will automatically move the robot to ensure that the cancer is always precisely targeted. This allows for higher doses of radiation to be delivered to the tumor each day, substantially shortening overall treatment times while minimizing the likelihood of unwanted side effects.

"For example, instead of up to 20 rounds of radiation over four weeks for prostate cancer, with the CyberKnife, patients will likely only need one week of highly targeted treatment. This could be game changing for New Zealand men."

Click here to learn more about the CyberKnife S7 System at Auckland Radiation Oncology.

Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.

About Auckland Radiation Oncology
Auckland Radiation Oncology is a joint venture, owned and operated by MercyAscot and Southern Cross Healthcare. Established in 2008 as the first private radiation therapy treatment centre in New Zealand, Auckland Radiation Oncology treats 70-100 patients daily requiring radiation therapy, from its purpose-built treatment centre in Epsom, Auckland. With an international reputation for being at the forefront of radiation therapy cancer treatment, Auckland Radiation Oncology offers patients a choice of leading-edge radiation therapy aimed directly at improving cancer treatment outcomes and quality of life.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, Twitter, and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to clinical applications, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace; and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on November 3, 2022, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact:
Beth Kaplan                                                                                                          
Public Relations Director, Accuray                                                                  
+1 (408) 789-4426                                                                                             
bkaplan@accuray.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-announces-first-patient-treatments-in-new-zealand-with-the-cyberknife-system-the-worlds-only-robotic-radiation-therapy-delivery-device-301722612.html

SOURCE Accuray Incorporated

FAQ

What is the CyberKnife S7 System?

The CyberKnife S7 System is a robotic radiation therapy device providing high-precision cancer treatments.

When did Accuray announce the CyberKnife S7 System's implementation in New Zealand?

Accuray announced the implementation on January 17, 2023.

How does the CyberKnife S7 System impact treatment times?

The system allows for significantly shorter treatment times compared to traditional radiation therapy, requiring only 1 week instead of up to 4 weeks.

What is the significance of the CyberKnife S7's use at Auckland Radiation Oncology?

It marks the first use of this advanced system in New Zealand, enhancing local cancer treatment capabilities.

What are the benefits of the CyberKnife S7 System over traditional methods?

It delivers radiation with sub-millimeter precision, minimizes damage to healthy tissues, and shortens overall treatment durations.